Related Experiment Video

Updated: Oct 15, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

746

LncRNAs Roles in Chemoresistance of Cancer Cells

Sina Taghvimi1, Sepideh Abbaszadeh2,3, Fatemeh Bahrami Banan2,3

  • 1Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.

Current Molecular Medicine
|October 29, 2021
PubMed

Insights

Long noncoding RNAs (lncRNAs) play crucial roles in cancer drug resistance by regulating gene expression. Understanding lncRNA functions offers potential for developing targeted therapies to overcome chemoresistance in cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer remains a significant global health challenge.
  • Drug resistance is a primary obstacle in effective cancer treatment.
  • The role of non-coding RNAs (ncRNAs) in drug resistance is an emerging area of research.

Purpose of the Study:

  • To review the features of long noncoding RNAs (lncRNAs).
  • To elucidate the regulatory roles of lncRNAs in gene expression linked to chemoresistance.
  • To explore the therapeutic potential of lncRNAs for personalized cancer treatment.

Main Methods:

  • Literature review of existing studies on lncRNAs and cancer drug resistance.
  • Analysis of lncRNA functions in gene regulation and cellular processes.
  • Evaluation of lncRNAs as biomarkers and therapeutic targets.

Main Results:

  • Long noncoding RNAs (lncRNAs) are transcripts >200 nucleotides with limited protein-coding potential.
  • lncRNAs are implicated in various pathological processes, including tumor formation and progression.
  • Evidence suggests lncRNAs significantly regulate gene expression involved in chemoresistance.

Conclusions:

  • lncRNAs are key players in cancer drug resistance mechanisms.
  • Targeting lncRNAs presents a promising strategy for overcoming chemoresistance.
  • Further research into lncRNAs can advance personalized cancer therapy approaches.
Keywords:
Drug resistanceLong non-coding RNAsNon-coding RNAscancerepithelial to mesenchymal transitionpersonalized treatment

More Related Videos

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.2K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K